# Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

> **NCT04365153** · PHASE2 · COMPLETED · sponsor: **The Cleveland Clinic** · enrollment: 45 (actual)

## Conditions studied

- COVID-19
- SARS-CoV 2

## Interventions

- **DRUG:** Canakinumab Injection 600mg
- **DRUG:** Canakinumab Injection 300mg
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04365153
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-24
- **Primary completion:** 2021-02-02
- **Final completion:** 2021-04-01
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2021-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04365153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04365153, "Canakinumab in Covid-19 Cardiac Injury (The Three C Study)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04365153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*